Unlike most targeted therapies, which act by inhibiting their target, a p53-targeted therapy must reactivate the protein, restoring its wild-type (WT)-like activity
It is classified as a triple incretin receptor agonist, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Because chronic inflammation is a key driver of tissue aging, oxidative stress, and impaired repair processes, this genotype may influence how efficiently the body maintains tissue integrity over time
Therefore, sufficient GSH supply and active glutathione peroxidase are main defence resources of neurons under pro-oxidative conditions 23,24,25